Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the launch of inClinico Agent, an advanced agentic AI workspace engineered to automate, optimize, and elevate clinical trial intelligence. Powered by a curated proprietary database of over 100,000 trials, endpoint-specific machine learning models, and specialized clinical analysis capabilities, inClinico Agent compresses months of complex clinical landscape analysis into minutes.

BUFFALO, NY - October 22, 2026 – A new case report was published in Volume 17 of Oncotarget on October 16, 2026, titled “Case Report WIN-MTB-2024001 – WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR.”

Annenberg surveys find that while just a quarter of Americans say they support the Make America Healthy Again movement, three times as many share the movement's food-related concerns.

Key findings include that every person’s genome includes around five million variants, or locations in the DNA that differ between individuals. These include around 10,000 that alter gene sequences, which can have a positive or negative effect – ranging from lactose intolerance to drug response – but are often biologically neutral. Every person also has between one and three rare variants that have previously been shown to cause serious genetic diseases, and another 50 rare variants that are currently of uncertain clinical relevance.

The team also analysed numerous polygenic risk scores, which take into account all known genetic factors to calculate risk of getting a disease in future. Looking at polygenic scores for 28 common conditions – such as diabetes, cardiovascular disease and schizophrenia – they found that most people would be categorised as at high risk  of genetic risk for around three conditions. The team did not investigate the health status of any of the participants, so many of these participants might not have any diseases. The study underlines that such findings can be part of normal genetic variation, and other factors are crucial in development of disease.

An interdisciplinary team of Manchester researchers will lead a major international project investigating how urbanisation, changing landscapes and human behaviour are influencing the spread of mosquito-borne diseases including chikungunya, Zika and dengue. 

Cancers can develop through epigenetic pathways even without driver gene mutations (DGMs), according to a study from Science Tokyo. Researchers uncovered the YAP1–TEAD–TET1 axis, which triggers DNA demethylation and activates multiple oncogenes in hepatocellular carcinoma. Suppressing TET1 reduced tumor formation in mice, while analysis of human liver disease data supported the relevance of these findings. This study reveals an alternative epigenetic route to cancer development and offers new insights into DGM-negative cancers.

FDA grants accelerated approval to Jemperli (dostarlimab), an immunotherapy treatment for rectal cancer, developed through pioneering research at Memorial Sloan Kettering Cancer Center (MSK) with critical early-stage funding from Swim Across America.

What if we could predict in early development, which antibiotics bacteria are most likely to become resistant to? In a review published in Nature Reviews Microbiology, researchers from the HUN-REN Biological Research Centre, Szeged (HUN-REN BRC Szeged) and the Hungarian Centre of Excellence for Molecular Medicine (HCEMM) in Szeged propose a five-step decision-making framework that could help identify resistance risks early, refine promising drug candidates and prevent costly failures.